Trial Profile
The Comparative Trial of UFT [tegafur/uracil] + TAM [tamoxifen] with CMF [cyclophosphamide + methotrexate + fluorouracil] + TAM in adjuvant therapy for breast cancer (CUBC)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Jul 2021
Price :
$35
*
At a glance
- Drugs Tegafur/uracil (Primary) ; Cyclophosphamide; Fluorouracil; Methotrexate; Tamoxifen
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 15 Sep 2009 Actual end date (1 Aug 2008) added as reported by ClinicalTrials.gov.
- 15 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Aug 2009 Results have been published in the British Journal of Cancer.